Cronos Group Inc.

TSX:CRON.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.57 -0.27%

-$0.01 today

Market cap
$1.67B
Beta
1.25
P/E (TTM)
-488.1
EPS (TTM)
-$0.01
52W Low $2.54High $4.66

Volume 0.15M

Average 0.19M

CRON.TO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Cronos Group Inc.TSX: CRON.TO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $26.05M rose 36.5% year over year, ahead of the +8.1% change in trailing-twelve-month cost of revenue. Sequentially, it fell 10.8% from the prior quarter. Over 3 fiscal years it compounded at +6.7% a year.

Context

  • Cost of revenue amounted to 58.6% of revenue in FY2025, down 15.5 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +36.5% holds above the trailing-twelve-month pace of +8.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$26.05M-10.8% QoQ
Last fiscal yearDec 2025
$87.45M+0.5% YoY
LTMMar 2026
$92.19M+8.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+36.5%——
1 year+0.5%——
3-year CAGR+6.7%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
87.45M USD
Year-over-year change
+0.5%
4-year CAGR
+1.8%

Cost of Revenue vs competitors

How CRON.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +8.1% is the 4th highest of 6, against a peer median of +19.7%.
  • Cost of revenue amounts to 57.8% of revenue for CRON.TO, versus a peer median of 63.0%.
CRON.TO Competitors
Cost of Revenue for CRON.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EXE.TOExtendicare Inc.LTM Jun 2026CA$1.2B CAD-9.7%+8.5%60.5%
SIA.TOSienna Senior Living Inc.LTM Sep 2026CA$954.54M CAD+19.7%+14.2%85.9%
WELL.TOWELL Health Technologies Corp.LTM Mar 2026CA$929.1M CAD+49.5%+48.8%63.0%
TLRY.TOTilray Brands, Inc.LTM Feb 2026$620.72M USD+5.1%+4.3%72.3%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$319.93M CAD+55.9%+24.4%62.7%
CRON.TOCronos Group Inc.LTM Mar 2026$92.19M USD+8.1%+6.7%57.8%
Peer median (excluding CRON.TO) —+19.7%+14.2%63.0%

Competitors are the stored peer set for CRON.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue64.02M87.54M87.03M117.5M149.15M
Cost of Revenue81.47M71.96M75.15M87.05M87.45M
Gross Profit(17.45M)15.58M11.88M30.45M61.7M
Gross Margin-27.3%17.8%13.7%25.9%41.4%
Research & Development21.66M13.25M5.83M4.22M4.53M
Selling, General & Admin120.67M101.64M80.74M76.74M75.01M
Operating Expenses272.09M128.01M96.48M106.91M79.54M
Depreciation & Amortization13.36M11.52M7.44M8.84M14.48M
EBITDA(150.79M)(93.81M)(72.28M)(45.37M)(2.94M)
EBITDA Margin-235.5%-107.2%-83.0%-38.6%-2.0%
Operating Income(289.54M)(112.44M)(84.6M)(76.46M)(17.84M)
Operating Margin-452.2%-128.4%-97.2%-65.1%-12.0%
Interest Income8.92M21.84M52.07M49.52M40.66M
Interest Expense00000
Other Income / Expenses162.1M(9.66M)11.1M113.01M419.21K
Income Before Tax(127.44M)(122.1M)(73.49M)36.55M(17.42M)
Pre-Tax Margin-199.1%-139.5%-84.4%31.1%-11.7%
Income Tax Expense(427.41K)34.48M(3.23M)(3.44M)(14.44M)
Net Income(392.81M)(170.26M)(73.79M)41.04M(9.61M)
Net Margin-613.5%-194.5%-84.8%34.9%-6.4%
EPS (Basic)(0.34)(0.42)(0.18)0.10(0.03)
EPS (Diluted)(0.34)(0.42)(0.18)0.10(0.03)
Weighted Avg Shares369.73M370.39M380.96M382.16M383.47M
Weighted Avg Shares (Diluted)370.39M370.39M380.96M382.16M383.47M

Cronos Group Inc.

TSX:CRON.TO

Intrinsic Alpha fair value

Locked

Current Price

$4.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.